Bringing hope
through the discovery and development of integrin-based therapies in underserved areas of medical need
Now enrolling!
See if you may qualify
Now enrolling!
See if you may qualify
Investigating NOVEL, TARGETED INTEGRIN-BASED THERAPIES FOR SERIOUS DISEASES
Our highly experienced drug development and clinical teams are focused on delivering new therapeutic options. Our lead drug candidate, PLN-101095, is an αvβ8 /αvβ1 integrin inhibitor currently being investigated in the FORTIFY trial for people with advanced or metastatic solid tumors.
Expanding our opportunities
We are also advancing additional programs that draw on the full potential of our proprietary integrin-based drug discovery and delivery platform.
Latest News
05-11-2026
Careers & Culture
We are passionate about bringing breakthrough therapies to people whose lives have been disrupted by serious diseases. See what makes Pliant such an inspiring and exciting place to work.
